KUALA LUMPUR (Nov 10): Careplus Group Bhd said some workers in its factory at the Senawang Industrial Estate in Negeri Sembilan have tested positive for Covid-19.
They are now under the care of a government hospital, the glove maker said in a statement.
“We had immediately taken necessary actions which include closure of the affected factory facilities, to facilitate thorough disinfection and sanitisation in accordance with the guidelines of the Ministry of Health (MoH),” the group said.
When contacted, Careplus executive director and group CEO Lim Kwee Shyan said the group has arranged for all of its 2,000 staff to undergo Covid-19 testing.
He declined to disclose how many workers have tested positive, saying the information will be released by the relevant authorities.
Lim said the operations at all its factories have been halted for two days, as they are all located at the same place.
As a result, the group’s production capacities will be affected during this period, he said, adding he expects production to resume gradually over the next two weeks.
Meanwhile, Careplus will continue with its glove shipments based on the availability of stocks in the warehouse.
According to Careplus’ 2019 annual report, the group has four factories with an annual total production capacity of 4.1 billion pieces of gloves.
In its statement, Careplus said it is working closely with MoH to perform contact tracing and is also making the necessary arrangements for employees in close contact with the affected workers, to undergo the swab test.
“They will be placed on home quarantine, pending their Covid-19 test results,” it stated.
The group said it has also immediately activated work from home arrangements for all non-critical employees.
“We will continue to work closely with MoH and will adhere to the guidelines and standard operating procedures to ensure the safety and wellbeing of our employees,” it added.
Careplus shares closed 31 sen or 8.96% lower at RM3.15 today, as glove counters came under selling, following news that Pfizer might be able to start Covid-19 vaccine production next year.
At current price, Careplus has a market capitalisation of RM1.73 billion. Some 35.18 million shares were traded.
Opportunity to buy on some bad news & on weakness. Workers will recover soon & back to normal. Nothing worrying with our good healthcare. Someone mentioned that "you make gloves to safe ppl but sendiri infected". Well, the workers are human too, they move around like us. How we wish, if you make gloves, covid won't go to you. Even hospital staff can get infected too. So we pray for the recovery of the infected workers.
Careplus has been added to the recent MSCI Global Small Cap Indexes. If anything, this means that funds have greater access and that those investing in the index would have to allocate funds to purchase Careplus. I see this as a great step forward in the longer term. Let not the market noise distract us from the fundamentals that have been tested and proven.
I really think retailer are very emotional, if you sell now u let banker collect cheap tickets. banker stakes are increasing since market opening. Do your own guess, what is going to happen in next few days.
"An analyst noted that forecasts for glove companies remained unchanged and estimated that local glove makers generally have orders secured up until the end of 2021." - UOB Kay Hian.
Hopefully, k+ can up 5-10% today.. as yesterday has down -8%.. its a good bargain/discount for the current price.. lets bring back the old price above 3.90..
+- 25% (from 3.15) growth room to get back the old price.. as u can see yesterday, IB has collecting.. today it self i can see still in the collecting mode since the price is affordable n cheap..
super_newbie - ya, furthermore k+ has added to MSCI index.. easy access cash n buyer tho.. we are lucky k+ has listed in the MSCI index..
So what should we worry..
1. Globe demand still there n more to come 2. K+ has stellar QR report (superb all time high QR) 3. Listed in MSCI index 4. All time Hight 5.88 , highest price before rally 4.14. 5. Today discounted price 6. Etc..the list goes on and on.. you may list on ur own.
So, apa lagi mau.. Catalyst is there..
Wee just need to be calm n control our emotions.. if not we will be lost..
Dont panic.. if u want panic, dont panic sell, but be a panic buy.. heheheheh..
Ppl keep throwing the negative talk just to want the price drop.. so they can buy cheap.. if u have no intentuon, why u bother to come here n bising2..
In klse, ada 1100 stocks.. from the pwnny to the procey price.. so why want to kacau here, if they are no intention to buy..
Be logic.. we cant stop them to spread the negativity.. bit we can stop ourself from throwing our ticket to the lowest price.. our ticket, we can hold no matter ppl talk bad..
Koey- true.. but Covid does not choose people to infect.. we cant control.. KKM staff also kena, police also kena.. as long as u are human, u still got chance to kena..
So thats mean, covid still there.. glove still in demand..
Hope above clarifies..
Its simple, If we want to sold car, we still want to sell to the highest we can get.. not below the market price right..
Or
if we have broken car, we shall want to sell to the highest price we can get also..
Many Asian countries aren't betting on the experimental shot to solve their COVID-19 crisis any time soon given the tropical heat, and a dearth of ultra-cold freezers. Health experts cautioned that the vaccine, should it be approved, was no silver bullet - not least because the genetic material it’s made from needs to be stored at temperatures of minus 70 degrees Celsius (-94 F) or below. Such requirements pose a particularly daunting challenge for countries in Asia, as well as in places like Africa and Latin America, where intense heat is often compounded by poor infrastructure that will make it difficult to keep the “cold chain” intact during deliveries to rural areas and islands. That is a problem for everyone in the world, given the World Health Organization estimates about 70% of people must be inoculated to end the pandemic, and Asia alone is home to more than 4.6 billion - or three-fifths of the global population. Some Asian countries are prioritising containing the novel coronavirus rather than looking to stockpile vaccines, while others are looking for alternatives to the messenger RNA technology used by Pfizer that requires such ultra-cold storage. “On the cold chain requirement of -70 degrees, that is a hefty requirement. We do not have such facility,” Philippines’ Health Secretary Francisco Duque told Reuters. “We will have to wait and see for now,” he added. “The technology Pfizer is using is new technology. We don’t have experience with that, so risks can be high.”
Kwon Jun-wook, an official at South Korea’s Disease Control and Prevention Agency (KDCA), said it wanted to see how vaccination progressed in other countries first and would thoroughly review its supply chain.
The country had recently experienced the problems of cold storage when it had to discard about 5 million doses of flu vaccines because they were not stored at recommended temperatures.
those who want to let go their ticket, maybe good for you to sell by this week.. so at least when the price start to hype, no one will throw and kacau the momentum.. just my2cents lol
For those want to enter/buy.. just wait for awhile.. wait the price to drop to the lowest he can.
Intraday player,better stay away as you might get stuck in this stock.. you may want to try ur luck in AT as the volume is there..easy to get n easy to sell..
Those who already holding, u may opt: 1. Topup 2. Average down 3. CL n reenter with the lowest price
You may wanted to study on your own.. n analyse ur risk appetite..
Pfizer yesterday took a giant step toward a COVID-19 vaccine, reporting that its vaccine candidate was effective in over 90% of uninfected clinical trial patients.
Reality check: It's a giant and welcome development, but the pandemic will be with us long after vaccine distribution begins.
Risk: 1. Panic on vaccine news 2. News is free/easy to come out. 3. Expected more vaccine news from other countries were spell out anytime. 4. Not to forget our political instability
Potential: 1. Demand across global 2. Some has secured the purchasing untill end of 2021 3. Good QR - expected qr will be up and fly every quarter. 4. Stellar comp performance from good profit. 5. K+ has added into MSCI Index
How to play glove stocks: 1. Must have holding power 2. Mid to long term 3. Emotions stability 4. Study the TA n FA
Be confident like AT traders.. no matter how bad the market or vaccine news, they still trust the share can fly n up.. this must admit they play well there..
KUALA LUMPUR (Nov 10): Careplus Group Bhd said some workers in its factory at the Senawang Industrial Estate in Negeri Sembilan have tested positive for Covid-19.
They are now under the care of a government hospital, the glove maker said in a statement.
“We had immediately taken necessary actions which include closure of the affected factory facilities, to facilitate thorough disinfection and sanitisation in accordance with the guidelines of the Ministry of Health (MoH),” the group said.
BFM News @NewsBFM · 48m Malaysia will review clinical trial data of Covid-19 vaccines first, before deciding to procure them. This comes after Pfizer and BioNTech announced that their vaccine is more than 90% effective in their phase three clinical trials.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Start_0f_the_bull
8,000 posts
Posted by Start_0f_the_bull > 2020-11-11 07:21 | Report Abuse
KUALA LUMPUR (Nov 10): Careplus Group Bhd said some workers in its factory at the Senawang Industrial Estate in Negeri Sembilan have tested positive for Covid-19.
They are now under the care of a government hospital, the glove maker said in a statement.
“We had immediately taken necessary actions which include closure of the affected factory facilities, to facilitate thorough disinfection and sanitisation in accordance with the guidelines of the Ministry of Health (MoH),” the group said.
When contacted, Careplus executive director and group CEO Lim Kwee Shyan said the group has arranged for all of its 2,000 staff to undergo Covid-19 testing.
He declined to disclose how many workers have tested positive, saying the information will be released by the relevant authorities.
Lim said the operations at all its factories have been halted for two days, as they are all located at the same place.
As a result, the group’s production capacities will be affected during this period, he said, adding he expects production to resume gradually over the next two weeks.
Meanwhile, Careplus will continue with its glove shipments based on the availability of stocks in the warehouse.
According to Careplus’ 2019 annual report, the group has four factories with an annual total production capacity of 4.1 billion pieces of gloves.
In its statement, Careplus said it is working closely with MoH to perform contact tracing and is also making the necessary arrangements for employees in close contact with the affected workers, to undergo the swab test.
“They will be placed on home quarantine, pending their Covid-19 test results,” it stated.
The group said it has also immediately activated work from home arrangements for all non-critical employees.
“We will continue to work closely with MoH and will adhere to the guidelines and standard operating procedures to ensure the safety and wellbeing of our employees,” it added.
Careplus shares closed 31 sen or 8.96% lower at RM3.15 today, as glove counters came under selling, following news that Pfizer might be able to start Covid-19 vaccine production next year.
At current price, Careplus has a market capitalisation of RM1.73 billion. Some 35.18 million shares were traded.